Immunoprophylactic strategies against respiratory influenza virus infection.
The objective of this report is to evaluate the prophylactic efficacy of liposome-mediated immunotherapy for prevention of respiratory influenza virus infection in mice. Antiviral antibody, interferon-gamma and poly (ICLC) were encapsulated in liposomes and they were evaluated for their ability to induce protective immunity against lethal influenza infection. Passive immunization using liposome-encapsulated antiviral antibody was found to offer complete protection against the virus challenge. However, this pretreatment must be administered within 24 h prior to virus challenge to be protective. Pretreatment with liposome-encapsulated interferon-gamma was found to stimulate cellular immune responses, but the protection is partial. Immunoprophylaxis using liposome-encapsulated double-stranded (ds) RNA poly (ICLC) provided complete and longer-lasting protection against influenza infection. These results suggest liposome-mediated immunoprophylactic approaches are effective in the prevention of respiratory influenza virus infection.
Saravolac
E G
EG
Chemical and Biological Defence Section, Defence Research Establishment Suffield, Box 4000 Station Main, Alberta, T1A 8K6, Medicine Hat, Canada.
Sabuda
D
D
Crist
C
C
Blasetti
K
K
Schnell
G
G
Yang
H
H
Kende
M
M
Levy
H B
HB
Wong
J P
JP
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D007371:Interferon-gamma / Q000008:administration & dosage; D008081:Liposomes; D051379:Mice; D011070:Poly I-C / Q000008:administration & dosage; D011994:Recombinant Proteins; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D008081:Liposomes; D011994:Recombinant Proteins; D007371:Interferon-gamma; D011070:Poly I-C